CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


SalineWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (11)


Name (Synonyms) Correlation
drug287 BCG-Denmark Wiki 0.38
drug489 COVID19 vaccine Wiki 0.38
drug982 GX-19 Wiki 0.38
drug1773 Patient management suffering of coronavirus infection Wiki 0.38
drug1538 N-803 Wiki 0.38
drug1785 Peginterferon lambda alfa-1a subcutaneous injection Wiki 0.38
drug736 Degarelix Wiki 0.38
drug1667 Observational Study Wiki 0.38
drug2933 online mindfulness group Wiki 0.38
drug1077 Human biological samples Wiki 0.38
drug647 Convalescent Plasma Wiki 0.08

Correlated MeSH Terms (13)


Name (Synonyms) Correlation
D009877 Endophthalmitis NIH 0.38
D002481 Cellulitis NIH 0.38
D054517 Orbital Cellulitis NIH 0.38
D000077062 Burnout, Psychological NIH 0.11
D013315 Stress, Psychological NIH 0.08
D007239 Infection NIH 0.06
D045169 Severe Acute Respiratory Syndrome NIH 0.06
D018352 Coronavirus Infections NIH 0.05
D055371 Acute Lung Injury NIH 0.04
D012127 Respiratory Distress Syndrome, Newborn NIH 0.04
D012128 Respiratory Distress Syndrome, Adult NIH 0.03
D003141 Communicable Diseases NIH 0.03
D011014 Pneumonia NIH 0.02

Correlated HPO Terms (2)


Name (Synonyms) Correlation
HP:0100658 Cellulitis HPO 0.38
HP:0002090 Pneumonia HPO 0.02

There are 7 clinical trials

Clinical Trials


1 Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection

This is a phase 2b prospective, randomized, single-blind, controlled trial of two weekly subcutaneous injections of lambda interferon alfa-1a versus placebo for prevention of SARS-CoV-2 infection in non-hospitalized participants at high risk for infection due to household exposure to an individual with coronavirus disease (COVID-19). The study will also evaluate the regimens participants with asymptomatic SARS-CoV-2 infection detected at study entry. All participants will be followed for up to 12 weeks.

NCT04344600 Sars-CoV2 Drug: Peginterferon lambda alfa-1a subcutaneous injection Other: Saline
MeSH:Infection

Primary Outcomes

Description: No evidence of SARS-CoV-2 infection at or before study day 28

Measure: Proportion of participants with no evidence of SARS-CoV-2 infection

Time: Up to 28 days

Description: Resolution of SARS-CoV-2 infection in the upper respiratory tract

Measure: Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples

Time: Up to 14 days

2 Clinical-trial of COVID-19 Convalescent Plasma in Outpatients

The overarching goal of this project is to confirm or refute the role of passive immunization as a safe and efficacious therapy in preventing the progression from mild to severe/critical COVID-19 illness and to understand the immunologic kinetics of anti-SARS-CoV-2 antibodies after passive immunization.The primary objective is to determine the efficacy and safety of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness. The secondary objective is to characterize the immunologic response to CP administration. This study will adults presenting to the emergency department (ED) with mild, symptomatic, laboratory-confirmed COVID-19 illness, who are at high risk for progression to severe/critical illness, but who are clinically stable for outpatient management at randomization.

NCT04355767 Covid19 Biological: Convalescent Plasma Biological: Saline

Primary Outcomes

Description: Disease progression defined as death or hospital admission or seeking emergency or urgent care within 15 days of randomization.

Measure: Number of patients with disease progression

Time: 15 days

Secondary Outcomes

Description: This scale was developed by a special World Health Organization (WHO) committee for quantifying COVID-19 illness severity. 8 = Death 7 = Hospitalized, intubated, mechanically ventilated and requiring additional organ support (pressors, renal replacement therapy) 6 = Hospitalized, intubated and mechanically ventilated 5 = Hospitalized on non-invasive ventilation or high flow nasal cannula 4 = Hospitalized on supplemental oxygen by mask or nasal prongs 3 = Hospitalized not on supplemental oxygen 2 = Not hospitalized with limitation in activity (continued symptoms) 1 = Not hospitalized without limitation in activity (no symptoms)

Measure: Worst severity rating on the WHO COVID Ordinal Scale for Clinical Improvement during the 30 days following randomization

Time: 30 days

Description: Time to disease progression on the COVID Outpatient Ordinal Outcome Scale censored at 15 days after randomization. Scale provides more granular detail for outpatients than the WHO scale (adapted from Harrell and Lindsell, 2020). Worsening of symptoms is defined as any subject admitted to the hospital (level 1), seen in the emergency room (level 2), a patient who reports increased symptoms of 2 levels on the scale over a 24 hour period, or a patient who reports increased symptoms of 1 level observed for a 48 hour period. COVID Outpatient Ordinal Outcomes Scale 1 = patient requires care in the hospital 2 = patient requires care in the ED or urgent care 3 = patient at home with symptoms rated as moderate (defined as fever, shortness of breath, abdominal pain) 4 = patient at home with symptoms rated as mild (defined as afebrile, constitutional symptoms (flu-like illness) without shortness 5 = patient in their usual state of health

Measure: Time to disease progression

Time: 15 days

Measure: Number of Hospital-free days during the 30 days following randomization

Time: 30 days

Measure: All-cause mortality

Time: Assessed at 30 days

3 Using BCG Vaccine to Enhance Non-specific Protection of Health Care Workers During the COVID-19 Pandemic. A Randomized Controlled Multi-center Trial

Background: The COVID-19 pandemic challenges the available hospital capacity, and this will be augmented by absenteeism of healthcare workers (HCW). HCW are at high risk, currently HCW constitute 20% of all the COVID-19 cases in Denmark. Strategies to prevent absenteeism of HCW are urgently needed. Bacille Calmette-Guérin (BCG) is a vaccine against tuberculosis, with protective non-specific effects against other infections; significant reductions in morbidity and mortality have been reported, and a plausible immunological mechanism has been identified. We hypothesize that BCG vaccination can reduce HCW absenteeism during the COVID-19 pandemic. Primary objective: To reduce absenteeism among HCW with direct patient contacts during the COVID-19 epidemic. Secondary objective: To reduce the number of HCW that are infected with SARS-CoV-2 during the COVID-19 epidemic and to reduce the number of hospital admissions amongst HCW with direct patient contacts during the COVID-19 epidemic. Study design: A multi-center randomized placebo controlled trial. Study population: 1500 HCW with direct patient contacts; defined as nurses, physicians and other medical staff working at emergency rooms and wards where COVID-infected patients are treated. Intervention: Participants will be randomized 1:1 to intradermal administration of a standard dose of BCG vaccine or placebo (saline). Main study parameters/endpoints: Primary endpoint: Number of days of (unplanned) absenteeism for any reason. Secondary endpoints: Number of days of (unplanned) absenteeism because of documented COVID infection. Cumulative incidence of hospital admissions. Risk for participants and impact: Based on previous experience and randomized controlled trials in adult and elderly individuals, the risks of BCG vaccination are considered low. The objective of this trial is to evaluate the potential beneficial effects of BCG vaccination through a lower work absenteeism rate of HCW and/or a mitigated clinical course of COVID infection.

NCT04373291 COVID-19 Non-specific Effects of Vaccines Morbidity Absenteeism Heterologous Immunity Biological: BCG-Denmark Biological: Saline

Primary Outcomes

Measure: Number of days of unplanned absenteeism for any reason

Time: 6 months

Secondary Outcomes

Measure: The cumulative incidence of documented COVID

Time: 6 months

Measure: The cumulative incidence of hospital admission for any reason

Time: 6 months

Measure: The number of days of unplanned absenteeism, because of documented COVID

Time: 6 months

Measure: The number of days of absenteeism, because of imposed quarantine as a result of exposure to SARS-CoV-2

Time: 6 months

Measure: The number of days of absenteeism, because of imposed quarantine as a result of having acute respiratory symptoms, fever or documented SARS- CoV-2 infection

Time: 6 months

Measure: The number of days of unplanned absenteeism because of self-reported acute respiratory symptoms

Time: 6 months

Measure: The number of days of self-reported fever (≥38 °C)

Time: 6 months

Measure: The number of days of self-reported acute respiratory symptoms

Time: 6 months

Measure: The cumulative incidence of self-reported acute respiratory symptoms

Time: 6 months

Measure: The cumulative incidence of death for any reason

Time: 6 months

Measure: The cumulative incidence of death due to documented COVID

Time: 6 months

Measure: The cumulative incidence of Intensive Care Admission for any reason

Time: 6 months

Measure: The cumulative incidence of Intensive Care Admission due to documented COVID

Time: 6 months

Measure: The cumulative incidence of Hospital Admission due to documented COVID

Time: 6 months

4 Phase 1b, Randomized, Blinded, Placebo-controlled Study of the Safety of Therapeutic Treatment With an Immunomodulary Agent (N-803 in Adults With COVID-19

This is a phase 1b, randomized, blinded, placebo-controlled study in adult subjects with COVID-19. This clinical trial is designed to assess the safety and immunostimulatory activity of N-803.

NCT04385849 COVID-19 Biological: N-803 Other: Saline

Primary Outcomes

Description: AEs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0

Measure: Preliminary safety and efficacy evaluation of N-803 by adverse event (AE) incidence

Time: 2 weeks

Description: The 7-point ordinal scale is an assessment of the clinical status and is performed as the first assessment on each study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen; 6) Not hospitalized, limitation on activities; 7) Not hospitalized, no limitations on activities.

Measure: Preliminary safety and efficacy evaluation of N-803 by subject clinical status using a the 7-point ordinal scale.

Time: 2 weeks

Measure: Preliminary safety and efficacy evaluation of N-803 by changes in lymphocyte counts

Time: 2 weeks

Secondary Outcomes

Description: National Early Warning Score (NEWS) is based on 7 clinical parameters: respiration rate, oxygen saturation, any supplemental oxygen, temperature, systolic blood pressure, heart rate, and level of consciousness.

Measure: Further evaluate efficacy of N-803 using changes to the National Early Warning Score (NEWS)

Time: 2 weeks

Measure: Further evaluate the safety of N-803 using change from baseline in hemoglobin

Time: 2 weeks

Measure: Further evaluate the safety of N-803 using change from baseline in platelets

Time: 2 weeks

Measure: Further evaluate the safety of N-803 using change from baseline in white blood cell count

Time: 2 weeks

5 Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization (HITCH): A Multicenter, Phase 2 Randomized Controlled Trial of Best Supportive Care (BSC) vs BSC Plus Degarelix

The purpose of this study is to determine if temporary androgen suppression improves the clinical outcomes of Veterans who are hospitalized to an acute care ward due to COVID-19.

NCT04397718 COVID-19 Drug: Degarelix Other: Saline

Primary Outcomes

Description: Determine if degarelix + best supportive care (BSC) as compared to placebo + BSC reduces the composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.

Measure: A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 15 after randomization.

Time: 15 days

Secondary Outcomes

Description: Determine if degarelix + BSC as compared to placebo + BSC reduces time to clinical improvement as defined by a decline of 2 categories or more from the baseline on the modified 7-category ordinal scale of clinical status of hospitalized influenza patients or hospital discharge whichever comes first.

Measure: Time to clinical improvement

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

Description: Determine if degarelix + BSC as compared to placebo + BSC reduces inpatient mortality.

Measure: Inpatient mortality

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

Description: Determine if degarelix + BSC as compared to placebo + BSC shortens the duration of hospitalization.

Measure: Duration of hospitalization

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

Description: Determine if degarelix + BSC as compared to placebo + BSC shortens the duration of intubation for mechanical ventilation.

Measure: Duration of intubation for mechanical ventilation.

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

Description: Determine if degarelix + BSC as compared to placebo + BSC reduces the time to normalization of temperature (T < 37.5 for 48 hours)

Measure: Time to normalization of temperature.

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

Description: Determine if degarelix + BSC as compared to placebo + BSC reduces the maximum severity of COVID-19 illness based on the modified 7-category ordinal scale of clinical status of hospitalized influenza patients. Score range 1-7, higher scores equals worse outcome.

Measure: Maximum severity of COVID19 illness.

Time: Through study completion/discharge (an average of 30 days with a maximum of 4 months)

Description: Determine if degarelix + best supportive care (BSC) as compared to placebo + BSC reduces the composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization.

Measure: A composite endpoint of mortality, ongoing need for hospitalization, or requirement for mechanical ventilation/extracorporeal membrane oxygenation (ECMO) at Day 30 after randomization.

Time: 30 days

6 A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects

The objective of our study is to evaluate safety, tolerability, and immunogenicity of COVID-19 preventive DNA vaccine in healthy volunteers.

NCT04445389 SARS-CoV-2 Drug: GX-19 Drug: Saline

Primary Outcomes

Description: solicited local and systemic AEs after vaccination

Measure: Incidence of solicited adverse events

Time: Through 1 year post vaccination

Description: unsolicited AEs after vaccination

Measure: Incidence of unsolicited adverse events

Time: Through 1 year post vaccination

Description: percentage of subjects with SAEs

Measure: Incidence of serious adverse events

Time: Through 1 year post vaccination

Secondary Outcomes

Description: Change from baseline in antigen-specific binding antibody titers

Measure: Geometric mean titer (GMT) of antigen-specific binding antibody titers

Time: Through 1 year post vaccination

Description: Seroconversion rate can be calculated based on test results reaching the quantifiable antibody level after vaccination

Measure: Percentage of subjects who seroconverted after vaccination

Time: Through 1 year post vaccination

Description: NAb is regarded as produced when FRNT50 is detected more than four times the baseline after vaccination

Measure: Geometric mean titer (GMT) of neutralizing antibody level

Time: Through 1 year post vaccination

Description: Change from baseline in antigen-specific binding antibody titers

Measure: Geometric mean fold rise (GMFR) of antigen-specific binding antibody titers

Time: Through 1 year post vaccination

Other Outcomes

Description: Antigen-specific IFN-γ T cell immune response assessed before/after vaccination

Measure: Change from baseline in antigen-specific IFN-g cellular immune response

Time: Through 1 year post vaccination

7 A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects

This is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2. To date, SARS-CoV-2 has infected over 4 million people worldwide resulted in the deaths of over three hundred thousand people.

NCT04453852 Coronavirus Infection COVID Biological: COVID19 vaccine Biological: Saline
MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome

Primary Outcomes

Description: Incidence of Adverse Events 1 week post immunisation

Measure: Incidence of Adverse Events

Time: 1 weeks post immunisation

Description: COVID19 neutralizing antibody titers post immunisation

Measure: COVID19 neutralizing antibody titers

Time: 2 weeks post second immunisation

Description: Frequency of COVID19 spike specific T cells 3 weeks post second immunisation

Measure: COVID19 T cell immunogenicity

Time: 3 weeks post second immunisation

Secondary Outcomes

Description: COVID19 spike specific antibody titers 6 months post second immunisation

Measure: Durability of antibody response

Time: 6 months post immunisation


No related HPO nodes (Using clinical trials)